J. B. Chemicals & Pharmaceuticals Limited reported earnings results for the second quarter and six months ended September 30, 2024. For the second quarter, the company reported sales was INR 10,006.2 million compared to INR 8,817.4 million a year ago. Revenue was INR 10,105.7 million compared to INR 8,894 million a year ago. Net income was INR 1,745.7 million compared to INR 1,505.9 million a year ago. Basic earnings per share from continuing operations was INR 11.24 compared to INR 9.72 a year ago. Diluted earnings per share from continuing operations was INR 11 compared to INR 9.54 a year ago.
For the six months, sales was INR 20,050.2 million compared to INR 17,779.4 million a year ago. Revenue was INR 20,208.6 million compared to INR 17,912.3 million a year ago. Net income was INR 3,514 million compared to INR 2,929 million a year ago. Basic earnings per share from continuing operations was INR 22.64 compared to INR 18.92 a year ago. Diluted earnings per share from continuing operations was INR 22.14 compared to INR 18.56 a year ago.
J.B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The Company specializes in gastroenterology, hypertension and dermatology. It is also focused on other therapeutic categories like nephrology, respiratory, virology, diabetes, and nicotine replacement therapy (NRT). The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). Its brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. It specializes in manufacturing of medicated and herbal lozenges. All its lozenges (herbal, medicated and soft-centered) can be made in sugar and sugar-free options. It has implemented osmotic-controlled release oral drug delivery system (OROS) technology. It maintains a direct presence in Russia and South Africa, along with distributor relationships in the United States and various markets throughout Asia, Africa, and Latin America.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
